Articles by Kan Hyeong-woo
Kan Hyeong-woo
hwkan@heraldcorp.com-
Unity poised to help creating innovative games
Unity Technologies, developer of world-leading 3D graphics engines, discussed ways to improve the optimization and convenience for creators using its game-making tools at its annual Unite conference, the company’s Korea branch said Monday. The in-person Unite 2022 conference took place in Austin, Brighton in England, Copenhagen in Denmark, Montreal and San Francisco on Tuesday as it was also virtually open for all developers across the world. Headquartered in the US, Unity operates the wor
Technology Nov. 7, 2022
-
Naver CEO voices confidence in data backup
Naver CEO Choi Soo-yeon on Monday underscored the IT giant’s data stability, pointing out that the company’s services are being provided soundly. “Established in 2013, data center Gak (Chuncheon) plays a linchpin role in offering (Naver’s) various services stably. With the high level of data backup and mirroring measures, we were able to normalize our services within a few hours in the wake of the recent fire at (SK C&C’s) data center,” said Choi in a conf
Technology Nov. 7, 2022
-
US expansion matter of when, not if: Samsung Biologics
Samsung Biologics, the world's leading contract development and manufacturing organization by production capacity, is reviewing overseas expansion options with a determined will to set up a production foothold in the US in the future. "The US expansion is happening eventually. It's not about 'if.' It's about 'when,'" James Park, Samsung Biologics’ chief business officer, told a group of reporters last week at the Convention on Pharmaceutical Ingredients in Frankfurt, Germ
Technology Nov. 7, 2022
-
Core consumer inflation hits 21-year high
The core consumer price index, an inflation barometer that measures consumer prices excluding food and energy, has increased by the largest margin in 21 years. Statistics Korea’s all items index logged 106.09 as of October this year, up 3.5 percent from the previous year’s January-to-October period. It was also the largest jump on year in 14 years. The index is an OECD standard for core inflation, which excludes food and energy because those prices are more volatile due to seasonal a
Economy Nov. 6, 2022
-
[Herald Interview] ‘One arm gets influenza, other arm gets COVID’
The novel coronavirus is likely to evolve into a flu-like respiratory virus by the end of 2023, or in 2024, once the COVID-19 pandemic reaches its endemic phase, eventually requiring people to get vaccinated year after year, a senior leader at Moderna said. “During the endemic period, the (COVID-19) vaccine will become available just like the influenza vaccine. You will be able to go online to a health center, do your pre-booking and pay for the vaccine exactly as you would for a flu vacci
Technology Nov. 3, 2022
-
Samsung Biologics underscores commitment to sustainability
FRANKFURT, Germany -- Samsung Biologics’ top official on Wednesday stressed the importance of contract development and manufacturing organization companies’ efforts to reduce greenhouse gas emissions and how the South Korean CDMO giant is working toward achieving environmental friendliness. “CDMOs play a huge part because we provide the manufacturing and logistics for a lot of (biopharmaceutical) companies and we have to continue to innovate together,” said James Choi, ex
Technology Nov. 3, 2022
-
[From the Scene] Korean firms' presence at CPhI triples this year
FRANKFURT, Germany -- The Convention on Pharmaceutical Ingredients (CPhI) Worldwide connected thousands within its community from Tuesday to Thursday in Frankfurt, Germany. Included on this global stage were 62 South Korean pharmaceutical and biopharmaceutical companies, tripling the country’s presence from the event last year. Based on the number of exhibitors by country, Korea ranked ninth of the 72 countries. Korea was also the only country that had two pavilions for exhibiting each nat
Industry Nov. 3, 2022
-
[Exclusive] SK Pharmteco’s French CDMO to complete construction of new plant in Q1 2023
FRANKFURT, Germany -- Yposkesi, SK Pharmteco’s French contract development and manufacturing organization specialized in cell and gene therapy, is expecting to complete the construction of its new plant by the end of the first quarter next year, the CDMO’s CEO said Tuesday. “After (the completion of the plant), we will qualify this manufacturing unit and we expect to get the authorization from the French authorities to operate the plant under the (Good Manufacturing Practice) b
Technology Nov. 2, 2022
-
[Herald Interview] ‘Biopharmas in midst of manufacturing revolution’
As biopharmaceutical companies across the globe are undergoing revolutionary changes in bioprocessing, Merck Life Science appears committed to helping Korean companies stay ahead of the game. Meeta Gulyani, head of strategy, business development and sustainability at Merck Life Science, told The Korea Herald last week that the factory of the future features connected, automated and digitized manufacturing. “All of this is to say that we are going to try to increase the speed of manufacturi
Technology Nov. 2, 2022
-
Celltrion seeks partnership expansion at CPhI Worldwide
FRANKFURT -- Celltrion, a South Korean pharmaceutical giant, is seeking to expand partnerships at this year’s Convention on Pharmaceutical Ingredients Worldwide, the company said Tuesday. Taking place in major European cities each year, CPhI is one of the largest global pharma industry events in the world that gathers household names and experts. The German city of Frankfurt is holding this year’s event from Tuesday to Thursday. According to Celltrion, the drug maker has set up an in
Technology Nov. 1, 2022
-
Samsung Biologics emphasizes speed
FRANKFURT, Germany -- Samsung Biologics, a leading South Korean contract development and manufacturing organization, has highlighted its speed in expanding production capacity and bringing clients’ drug products to the market as the company’s competitive edge in the global CDMO industry. “The most prominent differentiator is our speed to the market. We allow our customers to bring their products faster to the market,” said Kevin Sharp, Samsung Biologics’ vice presid
Technology Nov. 1, 2022
-
[Herald Interview] Strong intellectual property protection critical for drug innovation
Strong intellectual property protection is a key factor for pharmaceutical and biotechnology firms to become global household names, according to a high-ranking official at the International Federation of Pharmaceutical Manufacturers and Associations. “Because our industry is one of the most highly regulated industries, so what’s necessary in order to excel in that situation is, of course, the ability to innovate first and foremost. But that is only allowed through very strong intel
Technology Oct. 31, 2022
-
Samsung Biologics looks to woo global clients at CPhI Worldwide
FRANKFURT -- Samsung Biologics, the world’s largest contract manufacturing and development organization by production capacity, is looking to attract global customers at this year’s Convention on Pharmaceutical Ingredients Worldwide, officials said Monday. CPhI is one of the biggest international pharma industry events that draws leading businesses and professionals from across the globe. Taking place in major European cities each year, this year’s event is held in Frankfurt, G
Technology Oct. 31, 2022
-
Samsung's operating profit falls 30% amid grim outlook
Samsung Electronics' operating profits dropped by more than 30 percent on year, despite record sales, amid the weakening business environment in the semiconductor sector. According to Samsung Electronics on Thursday, the company logged 76.78 trillion won ($54 billion) in sales and 10.85 trillion won in operating profits in the third quarter. The company’s device solutions unit, which is in charge of Samsung’s chip businesses, saw its operating profits almost halve to 5.12 trillion wo
Technology Oct. 27, 2022
-
Boryung acquires Korean rights to Eli Lilly’s lung cancer drug
South Korean drug maker Boryung has acquired the selling rights of Alimta, a non-small cell lung cancer treatment developed by US pharmaceutical company Eli Lilly, for the local market. According to Boryung on Tuesday, the acquisition agreement also included the copyright and licensing rights of Alimta in the country. First introduced in Korea in 2006, Alimta was the first drug to significantly reduce the anti-cancer drug’s adverse effects and toxicity while improving the survival rate of
Technology Oct. 26, 2022
Most Popular
-
1
Ex-presidential official’s leaked phone call rattles conservative bloc
-
2
Man escapes DUI charges by downing bottle of soju while pulled over
-
3
Pay debate plagues foreign nanny pilot
-
4
K-pop star lip-syncing controversy flares up again
-
5
35% of S. Koreans view unification 'unnecessary'
-
6
Slew of top K-pop stars ready to return from military
-
7
Pianist Lim Yunchan double winner at Gramophone Awards
-
8
S. Korea, US clinch 2026-30 defense cost-sharing deal in pre-election push
-
9
[Reporter’s Notebook] Was Netflix film opening BIFF really a bad thing?
-
10
N. Korean leader's sister derides Seoul's Hyunmoo-5 missile as 'useless'